Of the 14 samples we assessed, WT1-CTLs from the 3 donors (Hem07, Hem14, and Hem15) led to AML cell death in 12/14 samples, with ≥ 20% cytotoxicity (≤ 80% viability post-CTL treatment) used as a cutoff for defining susceptibility to WT1 CTLs (Supplementary Table 1, Supplementary Fig. 6). This evidence concerns the gene WT1 and acute myeloid leukemia.